|1/9/2019||Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2019 AGM of Orion Corporation|
|10/30/2018||Composition of the Nomination Committee of Orion Corporation|
|10/24/2018||Orion Group Interim Report January-September 2018|
|10/24/2018||Orion and Bayer have completed the phase III trial of darolutamide in patients with non-metastatic castration-resistant prostate cancer - The primary endpoint was met|
|1/4/2019||Orion Corporation and Fifth Corner Inc join forces to research solutions for improving the quality of life of prostate cancer patients|
|12/4/2018||Orion acquires sales and distribution rights for certain European Countries for Parkinson's disease drug Stalevo|
|11/1/2018||Orion Research Foundation grants million euros for research in 2019|
|10/24/2018||Orion and Amgen to collaborate on the commercialisation of AMGEVITA® (biosimilar adalimumab) in Finland|
As the cost pressures on pharmaceutical companies increase, Orion needs to constantly improve its efficiency to stay competitive. In 2016, the company began a group-wide Lean program, where the entire staff is involved in a culture of continuous improvement. Orion’s shift toward Lean culture received the Lean Prize 2016 from Lean Association of Finland.
11 January 2017 | On 1st November 2016 the Innovative Medicines Initiative (IMI) together with an association of industrial partners came together to support PHAGO, an innovative research project devoted to the development of immunomodulatory therapies for Alzheimer’s disease (AD).